CJC-1295 vs Ipamorelin: What They Are, How They Differ, and What People Notice

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH with modifications to resist enzymatic degradation. It comes in two forms: without DAC (also called Mod GRF 1-29) with a 30-minute half-life, and with DAC (Drug Affinity Complex) extending the half-life to approximately 8 days.

Ipamorelin is a selective pentapeptide growth hormone secretagogue that stimulates GH release by activating the ghrelin receptor (GHS-R1a). Unlike other GH secretagogues such as GHRP-6, ipamorelin is considered highly selective — it stimulates GH release without significantly affecting cortisol, prolactin, or appetite in preclinical and early clinical studies.

CJC-1295 binds the GHRH receptor on pituitary somatotrophs and amplifies the natural GH release pulse. It does not initiate a new GH pulse on its own — it increases the amplitude of existing pulses. The DAC version binds albumin for extended circulation, providing sustained GHRH receptor stimulation over days rather than minutes.

Ipamorelin activates the ghrelin receptor (GHS-R1a) to initiate growth hormone release from the pituitary. Unlike GHRP-6 or GHRP-2, it shows minimal cross-reactivity with other hormone pathways. This selectivity means it stimulates a clean GH pulse without significant increases in cortisol, aldosterone, or prolactin in research models.

CJC-1295 and Ipamorelin are the most commonly stacked growth hormone peptides in research protocols. They appear together because they activate two different arms of the GH axis — CJC-1295 amplifies the GHRH signal while Ipamorelin initiates a pulse through the ghrelin receptor.

This dual-pathway approach mimics the body's natural GH control system more closely than either peptide alone. The combination is theorized to produce larger and more physiological GH pulses while maintaining the selectivity that makes Ipamorelin attractive over older secretagogues like GHRP-6.

Researchers compare them to understand whether one alone is sufficient or whether the combination provides meaningful synergy for GH output, IGF-1 elevation, and downstream effects on body composition and recovery.